DANA-FARBER CANCER INSTITUTE formed a three-year immuno-oncology lung cancer research collaboration with Johnson & Johnson Innovation and Janssen Biotech Inc.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
